PCCM Hub
Back to Library
ObstructiveCurrent Guideline Must Read⚡ High-Yield Board Topic

Global Strategy for Prevention, Diagnosis and Management of COPD: GOLD 2024 Report

Global Initiative for Chronic Obstructive Lung Disease (GOLD)·American Journal of Respiratory and Critical Care Medicine·2024
COPDGOLDGuidelinesABCD GroupsExacerbationsEosinophils
AI

AI-Generated Summary

Educational summary — always verify with primary source
Background

The GOLD report is the internationally recognized evidence-based guideline for COPD diagnosis, staging, and management, updated annually.

Study Design

Evidence-based guideline synthesis by an international expert panel.

Key Findings

GOLD 2024 key updates: (1) Refined ABCD grouping to ABE (E = exacerbation-prone); (2) Blood eosinophil count ≥300 guides ICS use; (3) Triple therapy recommended for Group E; (4) Lung cancer screening integration; (5) Updated exacerbation prevention strategies.

Clinical Bottom Line

Know the GOLD ABE classification, spirometric grades (GOLD 1–4), and treatment escalation algorithm. Eosinophil-guided ICS use is now central to COPD management. All PCCM board candidates must know GOLD criteria and treatment pathways.

Limitations & Caveats

Guideline — not a clinical trial. Updated annually; always check current version.

Read Full Article

Access the complete publication on PubMed

Open PubMed

Send Feedback

Help us improve PCCM Hub

What kind of feedback do you have?